Ameriprise
NWBO

Ameriprise’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Ameriprise’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-60
Closed – – 6169
2014
Q2 		$0 Buy
+60
New +$382 ﹤0.01% 5970

Other funds holding NWBO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise's NWBO Position: Q3 2014 in Review

Ameriprise sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2014, closing a stake of 60 shares.

Ameriprise first reported a position in NWBO in Q2 2014 and held it in 1 quarter. The position peaked at $0 in Q2 2014. 71 funds tracked by Wall St. Rank hold NWBO as of Q3 2014.

  • Ameriprise reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2014 after selling out during the quarter.
  • Ameriprise sold 60 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2014.
  • Ameriprise first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2014 and held it in 1 quarter.
  • Ameriprise's Northwest Biotherapeutics, Inc. Common stock position peaked at $0 in Q2 2014.
  • 71 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2014.

Based on Ameriprise's 13F filing for Q3 2014, filed 14 Nov 2014.